Bioprosthetic tissue preparation with synthetic hydrogels

• US 7,955,788 B2
• Filed: 10/18/2004
• Issued: 06/07/2011
• Est. Priority Date: 10/30/2003
• Status: Active Grant

• Current Assignee: Medtronic Incorporated (Medtronic Plc)
• Original Assignee: Medtronic Incorporated (Medtronic Plc)
• Inventors: Bezuidenhout, Deon, Oostheysen, Anel, Human, Paul, Zilla, Peter
• Primary Examiner(s): Wityshyn; Michael G
• Assistant Examiner(s): HANLEY, SUSAN MARIE
• Application Number:
  US10/967,365
• Publication Number:
  US 20050119736A1
• Time in Patent Office: 2,423 Days
• Field of Search: 435/1.1, 424/423, 623/2.42
• US Class Current: 435/1.1
• CPC Class Codes: A61L 27/3687 characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
• CPC Class Codes: A61L 27/507 for artificial blood vessels apparatus for applying cells on a blood vessel prosthesis A61F2/062
• CPC Class Codes: A61L 27/52 Hydrogels or hydrocolloids

Abstract

Methods for treating xenogenic tissue for implantation into a human body including in-situ polymerization of a hydrogel polymer in tissue, and tissue treated according to those methods, where the polymerization takes place in tissue that has not been fixed with glutaraldehyde. The polymerization may only fill the tissue, bind the polymer to the tissue, or cross-link the tissue through the polymer, depending on the embodiment. One method includes free radical polymerization of a first vinylic compound, and can include cross-linking through use of a second compound having at least two vinyl groups. Another method utilizes nucleophilic addition polymerization of two compounds, one of which can include PEG and can further include hydrolytically degradable regions. In one embodiment, applicants believe the in-situ polymerization inhibits calcification, and that the polymerization of tissue un-fixed by glutaraldehyde allows for improved penetration of the polymer. The methods find one use in the treatment of porcine heart valve tissue, intended to extend the useful life of the valves by inhibiting calcification. The incorporation of degradable hydrogel regions may initially fill the tissue and reduce any initial inflammatory response, but allow for later infiltration by cells to remodel the tissue.

Claims

1. A method for in vitro treatment of bioprosthetic-tissue for implantation into a human body, the method comprising:

providing bioprosthetic-tissue comprising amino groups and carboxyl groups;

providing a first compound having at least one vinyl moiety;

introducing the first compound into interstitial spaces of the tissue; and

polymerizing the first compound with a free radical initiator in the interstitial spaces of the tissue to form a hydrogel polymer,

wherein the vinyl moiety reacts with at least some of the amino groups to bind at least some of the hydrogel polymer to the tissue amino groups; and

essentially none of the tissue amino groups are cross-linked with glutaraldehyde;

whereby calcification in the bioprosthetic tissue is reduced post implantation.

2. The method of claim 1, wherein the free radical initiator is selected from the group consisting of thermal initiators, peroxy compounds, azo compounds, photo initiators, redox initiators, and radiation induced initiators.

18. The method of claim 1, further comprising capping at least some of the amino groups with a block capping agent.

19. The method of claim 18, wherein the capping provides non-reactive groups selected from the group alkyl, aryl, ether and alcohol groups.

20. The method of claim 18, wherein the block capping agent is selected from the group glycidyl ether (PGE), glyceral, propional, CHO(CH₂)_nCH₃, and CH₃CO(CH₂)_nCH₃, where n is an integer having a value or 0 or greater, and any combination thereof.

21. The method of claim 1, further comprising capping at least some of the carboxyl groups with a capping agent.

22. The method of claim 21, wherein the capping provides non-reactive groups selected from the group alkyl, aryl, ether and alcohol groups.

3. The method of 1, further comprising contacting a second compound that is different from the first compound to the tissue, and wherein the reacting includes cross-linking the second compound to the polymer.

4. The method of claim 3, wherein the second compound has at least two vinyl moieties.

5. The method of claim 4, wherein the second compound comprises PEG.

6. The method of claim 5, wherein the second compound comprises PEG in a compound backbone.

7. The method of claim 5, wherein the second compound comprises PEG in a compound sidearm.

8. The method of claim 3, wherein the second compound is selected from the group N,N′

-methylenebisacrylamide, N,N′

-(1,2-dihydroxyethylene)-bisacrylamide, polyethyleneglycol divinyl ether, and

9. The method of 1, wherein the first compound has the formula R₁R₂C═

CR₃R₄, wherein each of R₁, R₂, and R₃ is H or CH₃, and wherein R₄ is selected from the group alkyl, aryl, ether, acid, ester, amide, alcohol and amine.

10. The method of claim 9, wherein R₄ is selected from the group —

COOH, —

COOR₅, —

CONH₂, and —

CONHR₆, wherein R₅ is an alcohol, and wherein R₆ is an alkyl.

11. The method of claim 9, wherein R₄ is selected from the group —

COOH, —

COOR₅, —

CONH₂, and —

CONHR₆, wherein R₅ has the formula —

(—

CH₂—

)_n—

OH and n=1 or greater, and wherein R₆ has the formula —

(—

CH₂—

)_p—

CH₃ and p is 0 or greater.

12. The method of 1, wherein the first compound is selected from the group acrylamide, 2-hydroxy ethyl methacrylate, methyl crotonate, methyl acrylate, ethyl acrylate, N(hydroxymethyl) methacrylamide, methyl methacrylate, methacrylamide, and N(hydroxymethyl) acrylamide and any combinations thereof.

13. The method of claim 12, wherein the first compound is acrylamide.

14. The method of 1, wherein the first compound has at least two vinyl moieties.

15. The method of claim 14, wherein the first compound comprises PEG.

16. The method of claim 15, wherein the first compound comprises PEG in a compound backbone.

17. The method of claim 15, wherein the first compound comprises PEG in a compound sidearm.

23. The method of 1, further comprising capping at least some of the amino groups with an activation capping agent to provide essentially reactive groups covalently bonded to the amino groups.

24. The method of claim 23, wherein the activation capping agent is selected from the group allyl glycidyl ether, butadiene monoxide, 1,2-epoxy-5-hexene, and glycidyl methacrylate, and any combination thereof.

25. The method of 1, wherein the tissue is porcine tissue.